{"DataElement":{"publicId":"3351890","version":"1","preferredName":"Prostate Cancer Patient Computed Tomography Result Clinical TNM Finding Stage","preferredDefinition":"Text statement to describe the results of a CT scan performed on a patient with prostate cancer.","longName":"3350703v1.0:3351747v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3350703","version":"1","preferredName":"Prostate Carcinoma Patient Computed Tomography Result","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis._The result of an action.","longName":"3350696v1.0:3350701v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3350696","version":"1","preferredName":"Prostate Carcinoma Patient","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"C4863:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-630E-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3350701","version":"1","preferredName":"Computed Tomography Outcome","preferredDefinition":"A method of examining body organs by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis. :The result of an action.","longName":"C17204:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Computed Tomography","conceptCode":"C17204","definition":"A method of examining structures within the body by scanning them with X rays and using a computer to construct a series of cross-sectional scans along a single axis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-6351-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B655744C-6362-6963-E040-BB89AD433CD0","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3351747","version":"1","preferredName":"Prostate Cancer Clinical TNM Finding Scan Result Stage","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002_TNM staging performed with access to clinical information only._The data or image obtained by gathering information with a sensing device._The result of an action._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3351747v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Extraprostatic Extension, Regional Lymphadenopathy [e.g., cN1]","valueDescription":"Prostate Cancer cN1 TNM Finding v7","ValueMeaning":{"publicId":"3351759","version":"1","preferredName":"Prostate Cancer cN1 TNM Finding v7","longName":"3351759","preferredDefinition":"Prostate cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cN1 TNM Finding v7","conceptCode":"C89225","definition":"Prostate cancer with metastasis in regional lymph node(s). (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FF61-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FF7A-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Equivocal","valueDescription":"Equivocal","ValueMeaning":{"publicId":"2558729","version":"1","preferredName":"Equivocal","longName":"2558729","preferredDefinition":"Open to question; uncertain as a sign or indication; open to two or more interpretations; of uncertain nature or significance. ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Equivocal","conceptCode":"C86071","definition":"Open to question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B276-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FF2E-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Distant Metastasis [e.g., cM1]","valueDescription":"Prostate Cancer cM1 TNM Finding v7","ValueMeaning":{"publicId":"3351757","version":"1","preferredName":"Prostate Cancer cM1 TNM Finding v7","longName":"3351757","preferredDefinition":"Prostate cancer with distant metastasis. (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer cM1 TNM Finding v7","conceptCode":"C89228","definition":"Prostate cancer with distant metastasis. (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FF3B-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FF54-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"Extraprostatic Extension, Localized (e.g., seminal vesicles)","valueDescription":"Prostate Cancer pT3b TNM Finding","ValueMeaning":{"publicId":"2833389","version":"1","preferredName":"Prostate Cancer pT3b TNM Finding","longName":"2833389","preferredDefinition":"Prostate cancer extending beyond the capsule of the prostate gland, with involvement of the seminal vesicles. (from AJCC 6th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Cancer pT3b TNM Finding v6 and v7","conceptCode":"C48242","definition":"Prostate cancer with seminal vesicle invasion. (from AJCC 6th and 7th Eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"621F0959-1C73-56E5-E040-BB89AD435D85","latestVersionIndicator":"Yes","beginDate":"2009-02-04","endDate":null,"createdBy":"LEEB","dateCreated":"2009-02-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FF8E-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"},{"value":"No Evidence of Extraprostatic Extension","valueDescription":"No Evidence of Extraprostatic Extension","ValueMeaning":{"publicId":"3351760","version":"1","preferredName":"No Evidence of Extraprostatic Extension","longName":"3351760v1.00","preferredDefinition":"Diagnostic tests fail to detect presence of metastatic lesions._Situated outside of the prostate._The spread or migration of cancer cells through the wall of an organ into surrounding organs and/or adjacent tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No Evidence of Metastatic Disease","conceptCode":"C48558","definition":"Diagnostic tests fail to detect presence of metastatic lesions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Extraprostatic","conceptCode":"C25505","definition":"Situated outside of the prostate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Direct Extension","conceptCode":"C120271","definition":"The spread or migration of cancer cells through the wall of an organ into surrounding organs and/or adjacent tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FF99-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":"Concept annotation added for UPitt/TCGA.  Ylu, 02/19/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B65DD1CE-FFB2-0EF6-E040-BB89AD435AA2","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"ONEDATA","dateModified":"2012-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3351871","version":"1","preferredName":"Prostate Carcinoma Clinical TNM Finding Scan Outcome Stage","preferredDefinition":"Prostate carcinoma is one of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.  -- 2002:TNM staging performed with access to clinical information only.:The data or image obtained by gathering information with a sensing device.:The result of an action.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3351871v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prostate Carcinoma","conceptCode":"C4863","definition":"One of the most common malignant tumors afflicting men.  The majority of carcinomas arise in the peripheral zone and a minority occur in the central or the transitional zone of the prostate gland.  Grossly, prostatic carcinomas appear as ill-defined yellow areas of discoloration in the prostate gland lobes.  Adenocarcinomas represent the overwhelming majority of prostatic carcinomas.  Prostatic-specific antigen (PSA) serum test is widely used as a screening test for the early detection of prostatic carcinoma.  Treatment options include radical prostatectomy, radiation therapy, androgen ablation and cryotherapy.  Watchful waiting or surveillance alone is an option for older patients with low-grade or low-stage disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Clinical TNM Finding","conceptCode":"C48881","definition":"TNM staging performed with access to clinical information only.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Scan","conceptCode":"C17999","definition":"The data or image obtained by gathering information with a sensing device.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66D065F-1AD6-4C96-E040-BB89AD437AF5","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-13","modifiedBy":"ONEDATA","dateModified":"2012-01-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B65DD1CE-FDE0-0EF6-E040-BB89AD435AA2","latestVersionIndicator":"Yes","beginDate":"2012-01-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-01","changeDescription":"Released per approval by B.McClure-Shimel. mc 1/18/12","administrativeNotes":"2023.9.1 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]},{"publicId":"3787498","version":"1","longName":"TCGA 2.6 by Disease","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3787516","version":"1","longName":"PRAD","context":"NCIP"}]}],"AlternateNames":[{"name":"diagnostic_ct_abd_pelvis_result","type":"TCGA_XML_Name","context":"NCIP"}],"ReferenceDocuments":[{"name":"CT Scan Results","type":"Preferred Question Text","description":"CT Scan Results","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B66E5FC3-08D3-1D70-E040-BB89AD43721A","latestVersionIndicator":"Yes","beginDate":"2012-01-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-13","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Released by TCGA per approval from B.McClure-Shimel. mc 1/18/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}